ClinicalTrials.gg
CompletedNCT01494467Updated Feb 18, 2021Results posted

Phase 3 Papulopustular Rosacea Study

A Phase 3 interventional study of CD5024 and Azelaic acid 15% Gel in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 50 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
688
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
3rd of 11
688 · median 486
Started
2011
with 1 other
Phase 3
6 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
4 of 11
Galderma R&D

Among the 11 studies testing ivermectin in Rosacea, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 1st registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.

03

Conditions studied

  • Papulopustular Rosacea

Browse trials for

Keywords

  • PPR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),
  2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.

Exclusion criteria

Exclusion Criteria:

  1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,
  2. The subject has rosacea with more than two nodules on the face.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
688 participants (actual)

Study arms

  • Experimental
    CD5024

    CD5024 1% Cream

    Drug: CD5024

  • Placebo comparator
    CD5024 Vehicle

    CD5024 Vehicle Cream

    Drug: Azelaic acid 15% Gel

Interventions

  • DrugCD5024

    CD5024 1% Cream, once daily

  • DrugAzelaic acid 15% Gel

    Topical Gel applied twice daily

06

What researchers measure

Primary outcomes

  1. Success Rate

    Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)

    Time frame: Week 12

  2. Absolute Change in Inflammatory Lesion Count

    Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)

    Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

    Time frame: Baseline to Week 12

07

Results

Posted Jan 16, 2015

Participant flow

Part A Vehicle Control (12 Weeks)
Participant flow — Part A Vehicle Control (12 Weeks)
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started459229
Completed429208
Not completed3021
Withdrew: Pregnancy10
Withdrew: Adverse event64
Withdrew: Withdrawal by subject98
Withdrew: Protocol violation40
Withdrew: Lost to follow-up88
Withdrew: Other11
Withdrew: Lack of efficacy10
Part B Long Term Active Control 40 Weeks
Participant flow — Part B Long Term Active Control 40 Weeks
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started428208
Completed353159
Not completed7549
Withdrew: Pregnancy20
Withdrew: Lack of efficacy13
Withdrew: Adverse event35
Withdrew: Withdrawal by subject3224
Withdrew: Protocol violation35
Withdrew: Lost to follow-up2610
Withdrew: Other (noted in ecrf)82
Part C Safety Follow up (4 Weeks)
Participant flow — Part C Safety Follow up (4 Weeks)
MilestoneCD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% Gel
Started353159
Completed353159
Not completed00

Outcome measures

PrimarySuccess Rate

Percentage of subjects who achieve "Clear" (Score 0) or "Almost Clear" (Score 1) at Week 12 (ITT-LOCF) based on the Investigator Global Assessment (IGA) Score. Evaluation of papulopustular rosacea will be performed by the investigator based on the following 5 point scale: Clear = 0 (No inflammatory lesions present, no erythema); Almost Clear = 1 (Very few small papules/pustules, very mild erythema present); Mild = 2 (Few small papules/pustules, mild erythema); Moderate = 3 (Several small or large papules/pustules, moderate erythema); Severe = 4 (Numerous small and/or large papules/pustules, severe erythema)

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Success Rate
Percentage of participantsCD5024 1% CreamCD5024 Vehicle Cream
Success Rate40.118.8
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.001
PrimaryAbsolute Change in Inflammatory Lesion Count

Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesion count change
Absolute Change in Inflammatory Lesion Count
Lesion count changeCD5024 1% CreamCD5024 Vehicle Cream
Absolute Change in Inflammatory Lesion Count-22.2 ± 14.87-13.4 ± 14.48
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · ANCOVA · p = <0.001 · Mean difference (net): -8.22 · 95% CI -10.18 to -6.25
SecondaryPercent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)

Inflammatory lesion counts were conducted at each visit by the Investigator or study coordinator. Papules and pustules were counted separately on each of the five facial regions (forehead, chin, nose, right cheek, left cheek).

Time frame:
Baseline to Week 12
Reported as:
Mean · Percentage of change in lesion counts
Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)
Percentage of change in lesion countsCD5024 1% CreamCD5024 Vehicle Cream
Percent Change in Inflammatory Lesion Count From Baseline to Week 12 (ITT-LOCF)-65.7 ± 33.18-43.4 ± 38.42
Statistical analysis
  • CD5024 1% Cream vs CD5024 Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.001

Adverse events

Collected over Time of signed informed consent to study end (~ 58 wks). Treatment emergent adverse events - occurred on date of 1st use of medication or after, except those reported from Day 1 lab data as blood sample was to be drawn before the time of 1st dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5024 1% Cream - Part A—7/458 (1.5%)33/458 (7.2%)
CD5024 Vehicle Cream - Part A—4/230 (1.7%)26/230 (11.3%)
CD5024 1% Cream - Part B—13/428 (3%)102/428 (23.8%)
Azelaic Acid 15% Gel - Part B—4/208 (1.9%)47/208 (22.6%)
CD5024 1% Cream - Part C—0/353 (0%)4/353 (1.1%)
CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part C—1/159 (0.6%)3/159 (1.9%)
CD5024 1% Cream - Overall—18/460 (3.9%)125/460 (27.2%)
CD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall—9/231 (3.9%)64/231 (27.7%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventCD5024 1% Cream - Part ACD5024 Vehicle Cream - Part ACD5024 1% Cream - Part BAzelaic Acid 15% Gel - Part BCD5024 1% Cream - Part CCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part CCD5024 1% Cream - OverallCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall
HypertensionVascular disorders0/4581/2300/4281/2080/3530/1590/4602/231
NephrolithiasisRenal and urinary disorders0/4580/2300/4280/2080/3531/1590/4601/231
Angina pectorisCardiac disorders0/4580/2301/4281/2080/3530/1591/4601/231
Aortic valve stenosisCardiac disorders0/4580/2300/4281/2080/3530/1590/4601/231
HeadacheNervous system disorders0/4580/2300/4281/2080/3530/1590/4601/231
Transient ischaemic attackNervous system disorders0/4580/2300/4281/2080/3530/1590/4601/231
DiverticulitisInfections and infestations0/4580/2300/4281/2080/3530/1590/4601/231
Incisional herniaInjury, poisoning and procedural complications0/4580/2300/4281/2080/3530/1590/4601/231
Chest discomfortGeneral disorders0/4580/2300/4281/2080/3530/1590/4601/231
DepressionPsychiatric disorders2/4580/2300/4280/2080/3530/1592/4600/231
Most frequent other events
Most frequent other events
EventCD5024 1% Cream - Part ACD5024 Vehicle Cream - Part ACD5024 1% Cream - Part BAzelaic Acid 15% Gel - Part BCD5024 1% Cream - Part CCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Part CCD5024 1% Cream - OverallCD5024 Vehicle Cream/Azelaic Acid 15% Gel - Overall
NasopharyngitisInfections and infestations10/4586/23043/42818/2081/3531/15952/46023/231
Upper respiratory tract infectionInfections and infestations12/4588/23040/42817/2081/3532/15948/46023/231
SinusitisInfections and infestations9/4586/23020/4287/2082/3530/15930/46013/231
Skin irritationSkin and subcutaneous tissue disorders3/4587/2304/4288/2080/3530/1596/46015/231

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(Year)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Mean50.5 ± 12.3549.5 ± 12.1650.2 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Female314145459
Male14584229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
Hispanic or Latino563187
Not Hispanic or Latino403198601
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
American Indian or Alaska Native000
Asian10515
Native Hawaiian or Other Pacific Islander000
Black or African American6410
White438218656
More than one race000
Unknown or Not Reported527
Skin Photo Type
Skin Photo Type(Participants)CD5024 1% CreamCD5024 Vehicle Cream/Azelaic Acid 15% GelTotal
I482270
II21196307
III13971210
IV503181
V11718
VI022
08

Study locations

50 sites
  • Total Skin and Beauty
    Birmingham, Alabama 35205, United States
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Dermatology Specialists, Inc
    Oceanside, California 92056, United States
  • Integrated Research Group, Inc
    Riverside, California 92506, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • ATS Clinical Research
    Santa Monica, California 90404, United States
  • Redwood Dermatology Research
    Santa Rosa, California 95403, United States
  • FXM Research Corp Miami
    Miami, Florida 33175, United States
  • Leavitt Medical Associates of Florida dba Ameriderm Research
    Ormond Beach, Florida, United States
  • Atlanta Dermatology, Vein & Research Center, LLC
    Alpharetta, Georgia 30022, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Altman Dermatology Associates
    Arlington Heights, Illinois 60005, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Deaconess Clinic, Inc.
    Evansville, Indiana 47713, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dermatology Specialists Research
    Louisville, Kentucky 40202, United States
  • Northeast Dermatology Associates
    Beverly, Massachusetts 01915, United States
  • David Fivenson, MD, PLC
    Ann Arbor, Michigan 48103, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Dermatology Clinical Trials Unit
    Saint Louis, Missouri 63141, United States
  • Psoriasis Treatment Center of NJ
    West Windsor, New Jersey, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • DermResearch Center of New York, Inc
    Stony Brook, New York 11790, United States
  • High Point, North Carolina 27262, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • Philadelphia Institute of Dermatology
    Fort Washington, Pennsylvania 19034, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Paddington Research
    Philadelphia, Pennsylvania 19103, United States
  • Yardley Dermatology Associates
    Yardley, Pennsylvania 19067, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37922, United States
  • Dermatology Reserach Associates
    Nashville, Tennessee 17203, United States
  • Arlington Research Center, Inc
    Arlington, Texas 76011, United States
  • Stephen Miller MD
    San Antonio, Texas 78229, United States
  • San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Guildford Dermatology Specialists
    Surrey, British Columbia V3R 6A7, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1V6, Canada
  • The Guenther Dermatology Research Center
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1A8, Canada
  • North Bay Dermatology Centre, Inc
    North Bay, Ontario P1B 3Z7, Canada
  • The Centre for Dermatology & Cosmetic Surgery
    Richmond Hill, Ontario L4B 1A5, Canada
  • XLR8 Medical Research, Inc
    Windsor, Ontario N8W 1E6, Canada
  • International Dermatology Research, Inc
    Montreal, Quebec H3H 1V4, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitan
    Quebec, G1V 4X7, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2011
First posted
Dec 19, 2011
Start
Dec 2011
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results delay requested
Jan 27, 2014
Results first posted
Jan 16, 2015
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01494467
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Dec 2011
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Jan 16, 2015
Last update
Feb 18, 2021

Study contacts

Michael Graeber, M.D.
study director · Galderma R&D, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion